Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 3/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 11/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 10/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | NNMT | P40261 | 6/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21312814 | 0.90 | METTL3 (0.52) | METTL3PRMT5WDR77 | |
| SCHEMBL21312938 | 0.90 | METTL3 (0.41) | METTL3PRMT5WDR77DDB1CRBN | |
| SCHEMBL21312942 | 0.87 | PRMT5 (0.39) | METTL3PRMT5WDR77NNMT | |
| SCHEMBL18571897 | 0.85 | PRMT5 (0.46) | METTL3PRMT5WDR77NNMT | |
| SCHEMBL20049575 | 0.85 | PRMT5 (0.42) | METTL3PRMT5WDR77 | |
| SCHEMBL18572838 | 0.85 | PRMT5 (0.58) | METTL3PRMT5WDR77NNMT | |
| SCHEMBL18572002 | 0.84 | METTL3 (0.52) | METTL3PRMT5WDR77 | |
| SCHEMBL21313002 | 0.84 | PRMT5 (0.38) | METTL3PRMT5WDR77NNMT | |
| SCHEMBL28636049 | 0.84 | METTL3 (0.39) | METTL3PRMT5WDR77NNMT | |
| SCHEMBL23892543 | 0.83 | PRMT5 (0.46) | METTL3PRMT5WDR77NNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210371433-A1 | Novel Monocyclic And Bicyclic Ring System Substituted Carbanucleoside Analogues For Use As PRMT5 Inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-02 | — | — | US | disclosed |
| US-20190263833-A1 | NOVEL MONOCYCLIC AND BICYCLIC RING SYSTEM SUBSTITUTED CARBANUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-08-29 | — | — | US | disclosed |
| WO-2018065365-A1 | NOVEL MONOCYCLIC AND BICYCLIC RING SYSTEM SUBSTITUTED CARBANUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263833-A1 | NOVEL MONOCYCLIC AND BICYCLIC RING SYSTEM SUBSTITUTED CARBANUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT8 | METTL3 158/4885PRMT5 1/4885WDR77 94/4885 |
| US-20210371433-A1 | Novel Monocyclic And Bicyclic Ring System Substituted Carbanucleoside Analogues For Use As PRMT5 Inhibitors | PRMT5, PRMT1, PRMT8 | METTL3 153/4885PRMT5 1/4885WDR77 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.